Neovasc - NVCN Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc or view top-rated stocks.

1 brokerages have issued 12 month price targets for Neovasc's stock. Their NVCN stock forecasts range from $125.00 to $125.00. On average, they anticipate Neovasc's stock price to reach $125.00 in the next year. This suggests a possible upside of 1,510.8% from the stock's current price.
View analysts' price targets for Neovasc or view top-rated stocks among Wall Street analysts.

Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN stock has decreased by 33.8% and is now trading at $7.76.
View the best growth stocks for 2022 here.

Neovasc is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Neovasc.

Neovasc will be holding an earnings conference call on Thursday, August 11th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Neovasc Inc. (NASDAQ:NVCN) announced its quarterly earnings results on Thursday, May, 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $1.76. The medical equipment provider had revenue of $0.61 million for the quarter, compared to analysts' expectations of $0.80 million. Neovasc had a negative trailing twelve-month return on equity of 50.69% and a negative net margin of 1,192.20%.

Shares of Neovasc reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Protalix BioTherapeutics (PLX), Palatin Technologies (PTN), Amarin (AMRN).

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCN stock can currently be purchased for approximately $7.76.

Neovasc (NASDAQ:NVCN) has a market capitalization of $21.03 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.00) on an earnings per share basis.

Neovasc employs 49 workers across the globe.

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for Neovasc is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.